June 5, 2020
InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database. IRT team has significantly enhanced the interface taking into consideration the users’ experience of IRT application. The additional new panels are designed for more comfortable work with the database. A list of other improvements implemented:
Immune Response Template (IRT) is one of InSysBio projects developed for the storage of information on immune cells and their interaction. The main aim of the project is to simplify the search of the actual information on the detailed mechanisms of immune response and the development of dynamic QSP models. For instance, one of the latest InSysBio projects, the open source QSP model of COVID-19, is being created with the help of IRT Database. Thus, most of the cell lifecycles will be adopted from IRT.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
| ← | July 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
1.
14 Jul 2017 18:49
To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created
Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.
|
15
|
16
|
|
17
|
18
|
19
|
20
|
21
|
22
|
23
|
|
24
|
25
1.
25 Jul 2017 13:50
InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.
Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.
2.
25 Jul 2017 17:37
InSysBio will present at the American Conference on Pharmacometrics (ACoP8)!
Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.
|
26
|
27
|
28
|
29
|
30
|
|
31
| ||||||
Thank you for your message! We will get back to you shortly.
